|
| |
Price : 5 slides for 600 €
| CA3 Human, Prostate cancer |
| |
|
|
|
|
|
|
|
|
| |
Age |
Sex |
Organ |
Diagnosis |
Gleason |
TNM |
Stage |
PSA(ng/ml) |
| 1 |
60 |
M |
prostate |
adenocarcinoma |
9 |
T3N0M0 |
Ⅲ |
11,2 |
| 2 |
64 |
M |
prostate |
adenocarcinoma |
7 |
T2N0M0 |
Ⅱ |
30 |
| 3 |
71 |
M |
prostate |
adenocarcinoma |
9 |
T3N0M0 |
Ⅲ |
60,4 |
| 4 |
64 |
M |
prostate |
adenocarcinoma |
10 |
T3N0M0 |
Ⅲ |
7,4 |
| 5 |
59 |
M |
prostate |
adenocarcinoma |
9 |
T3N0M0 |
Ⅲ |
9,8 |
| 6 |
65 |
M |
prostate |
adenocarcinoma |
8 |
T4N0M0 |
Ⅳ |
34,9 |
| 7 |
73 |
M |
prostate |
adenocarcinoma |
7 |
T2N0M0 |
Ⅱ |
48,1 |
| 8 |
69 |
M |
prostate |
adenocarcinoma |
7 |
T2N0M0 |
Ⅱ |
10,6 |
| 9 |
62 |
M |
prostate |
adenocarcinoma |
7 |
T2N0M0 |
Ⅱ |
37,3 |
| 10 |
66 |
M |
prostate |
adenocarcinoma |
9 |
T3N0M0 |
Ⅲ |
1,2 |
| 11 |
60 |
M |
prostate |
adenocarcinoma |
9 |
T3N0M0 |
Ⅲ |
40 |
| 12 |
66 |
M |
prostate |
adenocarcinoma |
7 |
T3N0M0 |
Ⅲ |
8,4 |
| 13 |
70 |
M |
prostate |
adenocarcinoma |
7 |
T4N0M0 |
Ⅳ |
7 |
| 14 |
65 |
M |
prostate |
adenocarcinoma |
9 |
T3N0M0 |
Ⅲ |
17,5 |
| 15 |
67 |
M |
prostate |
adenocarcinoma |
9 |
T3N1M0 |
Ⅳ |
13,1 |
| 16 |
69 |
M |
prostate |
adenocarcinoma |
7 |
T3N0M0 |
Ⅲ |
1,1 |
| 17 |
63 |
M |
prostate |
adenocarcinoma |
9 |
T3N1M0 |
Ⅳ |
11,8 |
| 18 |
69 |
M |
prostate |
adenocarcinoma |
7 |
T3N0M0 |
Ⅲ |
17,6 |
| 19 |
70 |
M |
prostate |
adenocarcinoma |
7 |
T3N0M0 |
Ⅲ |
9 |
| 20 |
58 |
M |
prostate |
adenocarcinoma |
9 |
T3N0M0 |
Ⅲ |
5,8 |
| 21 |
58 |
M |
prostate |
adenocarcinoma |
7 |
T3N0M0 |
Ⅲ |
15,8 |
| 22 |
71 |
M |
prostate |
adenocarcinoma |
7 |
T2N0M0 |
Ⅱ |
31,4 |
| 23 |
70 |
M |
prostate |
adenocarcinoma |
7 |
T3N0M0 |
Ⅲ |
14,4 |
| 24 |
59 |
M |
prostate |
adenocarcinoma |
6 |
T2N0M0 |
Ⅱ |
18,3 |
| 25 |
63 |
M |
prostate |
adenocarcinoma |
9 |
T3N0M0 |
Ⅲ |
16,6 |
| 26 |
72 |
M |
prostate |
adenocarcinoma |
9 |
T3N0M0 |
Ⅲ |
. |
| 27 |
66 |
M |
prostate |
adenocarcinoma |
8 |
T3N0M0 |
Ⅲ |
10,8 |
| 28 |
70 |
M |
prostate |
adenocarcinoma |
6 |
T3N0M0 |
Ⅲ |
10,8 |
| 29 |
70 |
M |
prostate |
adenocarcinoma |
7 |
T2N0M0 |
Ⅱ |
. |
| 30 |
68 |
M |
prostate |
adenocarcinoma |
8 |
T3N0M0 |
Ⅲ |
26,9 |
| 31 |
63 |
M |
prostate |
adenocarcinoma |
10 |
T4N0M0 |
Ⅳ |
. |
| 32 |
57 |
M |
prostate |
adenocarcinoma |
7 |
T4N0M0 |
Ⅳ |
25 |
| 33 |
72 |
M |
prostate |
adenocarcinoma |
8 |
T4N0M0 |
Ⅳ |
16,8 |
| 34 |
70 |
M |
prostate |
adenocarcinoma |
8 |
T3N0M0 |
Ⅲ |
0,5 |
| 35 |
75 |
M |
prostate |
adenocarcinoma |
9 |
T3N0M0 |
Ⅲ |
98 |
| 36 |
62 |
M |
prostate |
adenocarcinoma |
9 |
T4N0M0 |
Ⅳ |
. |
| 37 |
63 |
M |
prostate |
adenocarcinoma |
9 |
T4N0M0 |
Ⅳ |
91 |
| 38 |
53 |
M |
prostate |
adenocarcinoma |
9 |
T4N0M0 |
Ⅳ |
161 |
| 39 |
63 |
M |
prostate |
adenocarcinoma |
8 |
T3N0M0 |
Ⅲ |
13 |
| 40 |
44 |
M |
prostate |
adenocarcinoma |
7 |
T3N0M0 |
Ⅲ |
. |
| 41 |
69 |
M |
prostate |
normal (match of #8) |
. |
. |
. |
. |
| 42 |
62 |
M |
prostate |
normal (match of #9) |
. |
. |
. |
. |
| 43 |
66 |
M |
prostate |
normal (match of #12) |
. |
. |
. |
. |
| 44 |
65 |
M |
prostate |
normal (match of #14) |
. |
. |
. |
. |
| 45 |
69 |
M |
prostate |
normal (match of #18) |
. |
. |
. |
. |
| 46 |
70 |
M |
prostate |
normal (match of #19) |
. |
. |
. |
. |
| 47 |
70 |
M |
prostate |
normal (match of #29) |
. |
. |
. |
. |
| 48 |
63 |
M |
prostate |
normal (match of #31) |
. |
. |
. |
. |
| 49 |
44 |
M |
prostate |
normal (match of #40) |
. |
. |
. |
. |
| 50 |
carbon |
| |
|
|
|
|
|
|
|
|
| TNM classification : prostate cancer (AJCC 5 th Edition) |
|
|
|
|
TNM Classification : Prostate carcinoma
T- Primary tumor
TX-primary tumor cannot be assessed
T0- No evidence of primary tumor
T1-Clinically inapparant tumor not palpable or visible by imaging
- T1a-Tumor incidental histologic finding in 5% or less of tissue resected
- T1b-Tumor incidental histologic finding in more 5% or less of tissue
resected
- T1c-Tumor identified by needle biospsy
T2-Tumor confined within the prostate
- T2a-Tumor involves one lobe
- T2b-Tumor involves two lobe
T3-Tumor extends through the prostate capsule
- T3a-Extracapsular extension
- T3b-Tumor invades seminal vesicle
T4-Tumor is fixed or invades adjacent structures other than seminal
vesicle: (blader neck,external sphincter, rectum, levator muscle and/or pelvic
wall
N-Disntant lymph nodes
NX-Regional lymph nodes cannot be assessed
N0-No regional lymph node metastasis
N1-Regional lymph [h node metastasis]
M-Disntant metastasis
MX-Disntant metastasis cannot be assessed
M0-No disntant metastasis
M1-Disntant metastasis
- M1a-Non-region lymph node(s)
- M1b-Bone(s)
- M1c-Other site(s)
General Information of the Tissue Array Slide
Applications
- Immunohistochemistry
- In situ hybridization, RNA or DNA
- Fluorescent in situ hybridization (FISH)
- In situ PCR, RNA or DNA
- TUNEL for apoptosis (Recommended procedures in www.tissue-array.com
-> protocol)
Storage and stability
- Individual slide is paraffin-coated and put in an air-tight pack with
inert gas.
- Tissue array slides are shipped in room temperature.
- If the slides are stored in 4 degree, they are good up to one year.
How processed
- Tissues were initially fixed with formalin except for some of the
animal tissues.
- Then, dehydrated with gradient ethanol; typically 1 hour each
progressive steps; 70%, 90%, 95%, 99%, 100% x 3 times.
- Cleared by xylene, three changes for 1 hour each.
- Infiltrated with 60°C paraffin, three changes for 1 hour each
- Microtoming in 4 µm thickness and put on silane coating slide from
Muto Pure Chemicals (Japan)
Before use
- Dry slides for 1 hour in a oven at 60 degree.
- Dewax slides in xylene for 4 minutes x 5 times
- Hydrate slides in 100%, 95% and 75% ethanol for 3 minutes x 2 times
each.
- Immerse slides in tap water for 5 minutes
Slide orientation
- In most of the slides with 59 or 60 cores, the orientation is as
below unless indicated otherwise. #60 location is usually filled with carbon
for orientation.
| 1 |
2 |
3 |
4 |
5 |
6 |
7 |
8 |
9 |
10 |
| 11 |
12 |
13 |
14 |
15 |
16 |
17 |
18 |
19 |
20 |
| 21 |
22 |
23 |
24 |
25 |
26 |
27 |
28 |
29 |
30 |
| 31 |
32 |
33 |
34 |
35 |
36 |
37 |
38 |
39 |
40 |
| 41 |
42 |
43 |
44 |
45 |
46 |
47 |
48 |
49 |
50 |
| 51 |
52 |
53 |
54 |
55 |
56 |
57 |
58 |
59 |
60 |
|